Biomarin Pharmaceutical annual gross profit
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biomarin Pharmaceutical Gross Profit Growth & History (BMRN)
Biomarin Pharmaceutical's gross profit was $2.50B for fiscal 2025.
View full Biomarin Pharmaceutical company overviewBiomarin Pharmaceutical annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.50B | $230.1M | +10.12% |
| 2024 | 2024-12-31 | $2.27B | $386.5M | +20.48% |
| 2023 | 2023-12-31 | $1.89B | $294.1M | +18.46% |
| 2022 | 2022-12-31 | $1.59B | $217.3M | +15.79% |
| 2021 | 2021-12-31 | $1.38B | $39.6M | +2.96% |
| 2020 | 2020-12-31 | $1.34B | −$8.4M | −0.62% |
| 2019 | 2019-12-31 | $1.34B | $168.6M | +14.34% |
| 2018 | 2018-12-31 | $1.18B | $104.1M | +9.71% |
| 2017 | 2017-12-31 | $1.07B | $164.6M | +18.15% |
| 2016 | 2016-12-31 | $907.2M | $169.3M | +22.95% |
| 2015 | 2015-12-31 | $737.9M | $110.9M | +17.68% |
| 2014 | 2014-12-31 | $627.0M | $166.9M | +36.28% |
| 2013 | 2013-12-31 | $460.1M | $51.2M | +12.52% |
| 2012 | 2012-12-31 | $408.9M | $51.6M | +14.43% |
| 2011 | 2011-12-31 | $357.3M | $51.4M | +16.78% |
| 2010 | 2010-12-31 | $306.0M | $47.2M | +18.26% |
| 2009 | 2009-12-31 | $258.7M | $14.8M | +6.05% |
| 2008 | 2008-12-31 | $244.0M | — | — |
Biomarin Pharmaceutical quarterly gross profit
Q2.09
Q3.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $786.9M | $111.6M | +16.52% |
| Q1 2026 | 2026-03-31 | $571.2M | −$22.4M | −3.77% |
| Q4 2025 | 2025-12-31 | $598.9M | −$12.3M | −2.02% |
| Q3 2025 | 2025-09-30 | $636.0M | $78.8M | +14.13% |
| Q2 2025 | 2025-06-30 | $675.3M | $93.8M | +16.12% |
| Q1 2025 | 2025-03-31 | $593.6M | $69.9M | +13.36% |
| Q4 2024 | 2024-12-31 | $611.2M | $102.9M | +20.24% |
| Q3 2024 | 2024-09-30 | $557.3M | $104.0M | +22.94% |
| Q2 2024 | 2024-06-30 | $581.6M | $116.9M | +25.16% |
| Q1 2024 | 2024-03-31 | $523.7M | $62.7M | +13.60% |
| Q4 2023 | 2023-12-31 | $508.3M | $117.4M | +30.03% |
| Q3 2023 | 2023-09-30 | $453.3M | $64.2M | +16.51% |
| Q2 2023 | 2023-06-30 | $464.7M | $54.0M | +13.15% |
| Q1 2023 | 2023-03-31 | $460.9M | $58.5M | +14.55% |
| Q4 2022 | 2022-12-31 | $390.9M | $60.8M | +18.43% |
| Q3 2022 | 2022-09-30 | $389.1M | $83.9M | +27.47% |
| Q2 2022 | 2022-06-30 | $410.7M | $36.0M | +9.62% |
| Q1 2022 | 2022-03-31 | $402.4M | $36.5M | +9.98% |
| Q4 2021 | 2021-12-31 | $330.1M | $4.1M | +1.25% |
| Q3 2021 | 2021-09-30 | $305.2M | $17.2M | +5.98% |
| Q2 2021 | 2021-06-30 | $374.6M | $43.1M | +13.00% |
| Q1 2021 | 2021-03-31 | $365.9M | −$24.8M | −6.36% |
| Q4 2020 | 2020-12-31 | $326.0M | −$32.6M | −9.08% |
| Q3 2020 | 2020-09-30 | $288.0M | −$76.2M | −20.91% |
| Q2 2020 | 2020-06-30 | $331.5M | $21.2M | +6.83% |
| Q1 2020 | 2020-03-31 | $390.7M | $79.1M | +25.40% |
| Q4 2019 | 2019-12-31 | $358.5M | $80.3M | +28.88% |
| Q3 2019 | 2019-09-30 | $364.1M | $51.3M | +16.41% |
| Q2 2019 | 2019-06-30 | $310.3M | $16.5M | +5.62% |
| Q1 2019 | 2019-03-31 | $311.6M | $20.4M | +7.02% |
| Q4 2018 | 2018-12-31 | $278.2M | −$4.1M | −1.46% |
| Q3 2018 | 2018-09-30 | $312.8M | $38.1M | +13.89% |
| Q2 2018 | 2018-06-30 | $293.8M | $32.7M | +12.52% |
| Q1 2018 | 2018-03-31 | $291.1M | $37.4M | +14.73% |
| Q4 2017 | 2017-12-31 | $282.3M | $46.4M | +19.65% |
| Q3 2017 | 2017-09-30 | $274.7M | $45.5M | +19.86% |
| Q2 2017 | 2017-06-30 | $261.1M | $12.6M | +5.08% |
| Q1 2017 | 2017-03-31 | $253.7M | $60.1M | +31.05% |
| Q4 2016 | 2016-12-31 | $235.9M | $56.1M | +31.16% |
| Q3 2016 | 2016-09-30 | $229.2M | $55.2M | +31.70% |
| Q2 2016 | 2016-06-30 | $248.5M | $36.4M | +17.18% |
| Q1 2016 | 2016-03-31 | $193.6M | $21.7M | +12.62% |
| Q4 2015 | 2015-12-31 | $179.9M | −$11.2M | −5.85% |
| Q3 2015 | 2015-09-30 | $174.0M | $27.4M | +18.67% |
| Q2 2015 | 2015-06-30 | $212.1M | $51.5M | +32.07% |
| Q1 2015 | 2015-03-31 | $171.9M | $43.2M | +33.55% |
| Q4 2014 | 2014-12-31 | $191.1M | $61.5M | +47.43% |
| Q3 2014 | 2014-09-30 | $146.6M | $37.8M | +34.74% |
| Q2 2014 | 2014-06-30 | $160.6M | $46.3M | +40.56% |
| Q1 2014 | 2014-03-31 | $128.7M | $21.3M | +19.83% |
| Q4 2013 | 2013-12-31 | $129.6M | $24.2M | +22.96% |
| Q3 2013 | 2013-09-30 | $108.8M | $5.3M | +5.14% |
| Q2 2013 | 2013-06-30 | $114.2M | $13.8M | +13.74% |
| Q1 2013 | 2013-03-31 | $107.4M | $7.9M | +7.92% |
| Q4 2012 | 2012-12-31 | $105.4M | $19.1M | +22.10% |
| Q3 2012 | 2012-09-30 | $103.5M | $12.5M | +13.76% |
| Q2 2012 | 2012-06-30 | $100.4M | $9.1M | +9.93% |
| Q1 2012 | 2012-03-31 | $99.5M | $10.9M | +12.28% |
| Q4 2011 | 2011-12-31 | $86.3M | $5.2M | +6.39% |
| Q3 2011 | 2011-09-30 | $91.0M | $11.2M | +14.09% |
| Q2 2011 | 2011-06-30 | $91.4M | $13.8M | +17.82% |
| Q1 2011 | 2011-03-31 | $88.7M | $21.1M | +31.27% |
| Q4 2010 | 2010-12-31 | $81.1M | — | — |
| Q3 2010 | 2010-09-30 | $79.7M | $13.9M | +21.13% |
| Q2 2010 | 2010-06-30 | $77.5M | $14.6M | +23.21% |
| Q1 2010 | 2010-03-31 | $67.5M | — | — |
| Q3 2009 | 2009-09-30 | $65.8M | — | — |
| Q2 2009 | 2009-06-30 | $62.9M | — | — |
Biomarin Pharmaceutical gross profit trends
Over the last five fiscal years, Biomarin Pharmaceutical's gross profit increased from $1.34B to $2.50B, a change of $1.17B. The latest reported quarter, Q2 2026, shows $786.9M.
About the metric
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
Calculation and source
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biomarin Pharmaceutical source filings ↗